II/III期三阴性乳腺癌放疗联合同期顺铂的1期剂量递增试验
该前瞻性1B期试验评估早期三阴性乳腺癌女性放疗联合同期顺铂的安全性和最大耐受剂量。保乳术队列最大耐受剂量为40 mg/m2,乳房切除术队列为30 mg/m2,推荐2期剂量分别为40 mg/m2和30 mg/m2每周静脉给药。
要点
- 保乳术队列顺铂最大耐受剂量为40 mg/m2每周静脉给药
- 乳房切除术队列顺铂最大耐受剂量为30 mg/m2每周静脉给药
- 3年无病生存率保乳术队列74.7%,乳房切除术队列64.4%
核心结论
- 辅助放疗联合同期顺铂可行,保乳术和乳房切除术队列推荐2期剂量分别为40 mg/m2和30 mg/m2每周静脉给药。
研究设计与样本
- 前瞻性1B期试验,2013至2018年入组55例II或III期三阴性乳腺癌患者。
- 顺铂起始10 mg/m2每周静脉给药,按3+3设计以10 mg/m2递增至40 mg/m2或最大耐受剂量。
- 保乳术和乳房切除术患者进入平行队列进行剂量递增,随后在最大耐受剂量下扩展10例。
主要发现
- 4例患者出现剂量限制性毒性。
- 保乳术队列1例接受40 mg/m2出现耳鸣导致顺铂延迟,故40 mg/m2为该队列最大耐受剂量。
- 乳房切除术队列1例接受20 mg/m2出现3级尿路感染,另2例在40 mg/m2出现剂量限制性毒性(3级中性粒细胞减少和2级耳鸣)均导致顺铂延迟,故30 mg/m2为该队列最大耐受剂量。
- 中位随访48.5个月,3年无病生存率保乳术队列74.7%,乳房切除术队列64.4%。
关键数值与推荐
- 保乳术队列最大耐受剂量为顺铂40 mg/m2每周静脉给药。
- 乳房切除术队列最大耐受剂量为顺铂30 mg/m2每周静脉给药。
- 推荐2期剂量:乳房切除术队列30 mg/m2,保乳术队列40 mg/m2,每周静脉给药。
临床怎么用
- 早期三阴性乳腺癌辅助放疗时,可考虑联合同期顺铂,保乳术患者推荐2期剂量40 mg/m2每周,乳房切除术患者30 mg/m2每周。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with triple-negative breast cancer (TNBC) experience higher local-regional recurrence rates than those with luminal or HER2-positive tumors. This prospective, phase 1B trial was designed to assess the safety and to establish the maximum tolerated dose (MTD) of cisplatin with radiation therapy for women with early-stage TNBC. METHODS AND MATERIALS: Eligible patients had stage II or III TNBC. Cisplatin was initiated at 10 mg/m2 intravenously once weekly during radiation and then escalated in a 3 + 3 design by 10 mg/m2 at each dose level until 40 mg/m2, or the MTD, was reached. Patients undergoing breast-conserving therapy (BCT) or mastectomy were accrued in separate parallel cohorts during dose escalation, followed by a 10-patient expansion at the MTD. RESULTS: During 2013 to 2018, 55 patients were accrued. Four patients developed dose-limiting toxicity. In the BCT cohort, 1 patient receiving 40 mg/m2 developed tinnitus resulting in a cisplatin delay; therefore, this was the BCT cohort MTD. In the mastectomy cohort, 1 patient receiving 20 mg/m2 developed a grade 3 urinary infection, and 2 additional patients had dose-limiting toxicities at 40 mg/m2 (grade 3 neutropenia and grade 2 tinnitus), both resulting in cisplatin delay. Thus, 30 mg/m2 was the mastectomy cohort MTD. Median follow-up was 48.5 months. Three-year disease-free survival was 74.7% for the BCT cohort and 64.4% for the mastectomy cohort. CONCLUSIONS: Adjuvant radiation therapy with concurrent cisplatin is feasible with a recommended phase 2 dose of 30 mg/m2 and 40 mg/m2 intravenously weekly in mastectomy and BCT cohorts, respectively.
引用
- Bellon JR, Chen YH, Rees R, et al. A Phase 1 Dose-Escalation Trial of Radiation Therapy and Concurrent Cisplatin for Stage II and III Triple-Negative Breast Cancer. Int J Radiat Oncol Biol Phys. 2021. PMID: 33713742. doi:10.1016/j.ijrobp.2021.03.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。